Factorial Partners LLC Raises Holdings in Solventum Co. (NYSE:SOLV)

Factorial Partners LLC increased its position in shares of Solventum Co. (NYSE:SOLV - Free Report) by 11.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 74,800 shares of the company's stock after purchasing an additional 7,800 shares during the quarter. Solventum accounts for approximately 3.0% of Factorial Partners LLC's investment portfolio, making the stock its 6th largest holding. Factorial Partners LLC's holdings in Solventum were worth $5,215,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of SOLV. Tokio Marine Asset Management Co. Ltd. increased its holdings in Solventum by 4.2% in the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,966 shares of the company's stock valued at $346,000 after buying an additional 200 shares in the last quarter. National Bank of Canada FI increased its stake in Solventum by 4.0% in the 2nd quarter. National Bank of Canada FI now owns 6,093 shares of the company's stock valued at $314,000 after buying an additional 236 shares during the period. IVC Wealth Advisors LLC increased its position in Solventum by 5.0% during the third quarter. IVC Wealth Advisors LLC now owns 6,649 shares of the company's stock worth $464,000 after acquiring an additional 318 shares during the period. Copeland Capital Management LLC bought a new position in Solventum in the 3rd quarter valued at $26,000. Finally, Mather Group LLC. bought a new position in shares of Solventum in the 3rd quarter worth $27,000.

Analysts Set New Price Targets

Several brokerages have issued reports on SOLV. Stifel Nicolaus began coverage on Solventum in a research note on Tuesday, October 8th. They issued a "buy" rating and a $82.00 price target on the stock. Morgan Stanley boosted their target price on shares of Solventum from $60.00 to $73.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Wolfe Research started coverage on Solventum in a research note on Thursday, September 26th. They set a "peer perform" rating for the company. BTIG Research began coverage on shares of Solventum in a research note on Thursday, September 5th. They set a "neutral" rating for the company. Finally, Piper Sandler boosted their price objective on Solventum from $71.00 to $75.00 and gave the company a "neutral" rating in a research report on Friday, November 8th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, Solventum presently has a consensus rating of "Hold" and a consensus price target of $68.00.

Solventum Stock Up 2.0 %

SOLV stock traded up $1.34 during trading on Wednesday, reaching $68.39. 952,912 shares of the stock were exchanged, compared to its average volume of 1,719,540. The company has a quick ratio of 0.83, a current ratio of 1.15 and a debt-to-equity ratio of 2.45. Solventum Co. has a twelve month low of $47.16 and a twelve month high of $96.05. The stock has a 50 day simple moving average of $70.51 and a 200-day simple moving average of $62.21.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.